Table 1 Demographics and clinical characteristics 12 months prior to and 12 months following MITT initiation.
12 months prior to MITT (pre-index) (N = 1204) | 12 months following MITT (post-index) (N = 1204) | |
|---|---|---|
Demographics | ||
Female, n (%) | 851 (70.7) | |
Age at asthma diagnosis, mean (SD) | 45.2 (15.9) | |
Age at MITT initiation, mean (SD) | 54.8 (13.8) | |
Years from diagnosis to MITT, mean (SD) | 9.6 (8.9) | |
Urban location, n (%) | 1,023 (85.0) | |
Smoking status, n (%) | ||
Non-smokera | 708 (58.8) | 717 (59.6) |
Smoker | 208 (17.3) | 199 (16.5) |
Former smoker | 247 (20.5) | 272 (22.6) |
Unknown | 41 (3.4) | 16 (1.3) |
BMIb | n = 640 | n = 536 |
BMI, mean (SD) kg/m2 | 30.3 (6.2) | 30.9 (6.3) |
Spirometryc, mean (SD) | n = 387 | n = 281 |
FEV1 % predicted value | 70.8 (19.1) | 75.4 (19.6) |
FEV1/FVC ratio | 70.1 (13.1) | 73.6 (13.3) |
Common comorbidities, n (%) | ||
Anxiety/depression | 459 (38.1) | |
Pneumonia | 57 (4.7) | |
Other respiratory infections | 373 (31) | |
Rhinitis | 232 (19.3) | |
Hypertension | 409 (34.0) | |
Diabetes mellitus | 139 (11.5) | |
Gastroesophageal reflux | 112 (9.3) | |
Conjunctivitis | 12 (10.0) | |
Polyposis | 76 (6.3) | |
Severe exacerbationsd; n (%) | 667 (55.4) | 503 (41.8) |
Blood eosinophils (%), mean (SD) | n = 732 4.1 (3.4) | n = 717 4.1 (3.1) |
